Trials / Withdrawn
WithdrawnNCT00474409
A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation
A Multicenter, Placebo-Controlled, Double-Blind Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy and safety of Betahistine Mesilate in the treatment of patients with vertigo caused by Cerebral Infarction in posterior circulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Merislon |
Timeline
- Start date
- 2007-05-01
- First posted
- 2007-05-16
- Last updated
- 2017-06-05
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00474409. Inclusion in this directory is not an endorsement.